Lir Life SciencesBBCMF -80.00%15 EBIT per Share is $-0.06 as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,184 Biotechnology companies, Lir Life Sciences ranks worse than 84459.38% on this metric.
Lir Life Sciences's EBIT per Share for the
three
months ended in Jan. 2026 was $-0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.06.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Lir Life Sciences's EBIT per Share or its related term are showing as below:
BBCMF's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.45 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Lir Life Sciences (OTCPK:BBCMF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lir Life Sciences EBIT per Share Related Terms
Lir Life Sciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lir Life Sciences (BBCMF) has a EBIT per Share of $-0.06 as of Jan. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #999999 out of 1184 companies in the Biotechnology industry.
Is Lir Life Sciences' EBIT per Share too high?
Lir Life Sciences' current EBIT per Share is $-0.06. Based on the distribution chart, Lir Life Sciences ranks #999999 out of 1184 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #999999 out of 1184 companies for EBIT per Share. This places Lir Life Sciences in the lower half of its industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,184 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current EBIT per Share is $-0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current EBIT per Share of $-0.06. The current EBIT per Share is $-0.06. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current EBIT per Share is $-0.06 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for BBCMF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 